Russia’s mRNA Cancer Vaccines Show Promising Results in Tumor Reduction

DID Press: Two new Russian therapeutic cancer vaccines, designed individually based on the genetic profile of patients’ tumors, have entered clinical use after showing promising results in early trials.

Russian scientific and medical institutions have developed two personalized mRNA-based cancer vaccines that are tailored to the genetic characteristics of each patient’s tumor.

The first vaccine, branded “EnteroMix” and developed by Russia’s Federal Medical and Biological Agency, is designed for the treatment of colorectal cancer. The vaccine successfully completed its first phase of clinical trials in 2025 involving 48 patients.

Clinical results showed a 100 percent immune response rate, with some cases reporting a 60 to 80 percent reduction in tumor growth.

The second advanced project, known as “NeoOncoVac,” was developed by the Gamaleya Research Center for treating melanoma, one of the most aggressive forms of skin cancer. Official reports indicate that treatment of the first patient using this vaccine began in April 2026.

Experts emphasize that these vaccines are not preventive vaccines; instead, they are designed as therapeutic treatments for patients already diagnosed with cancer.

Following the positive results of the two projects, Russia’s Ministry of Health has proposed including these advanced treatments in the national mandatory health insurance program from 2026, allowing eligible patients to access the technology without direct payment.